226 related articles for article (PubMed ID: 16482569)
21. Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients.
Kobayashi K; Noguchi M; Itoh K; Harada M
Cancer Sci; 2003 Jul; 94(7):622-7. PubMed ID: 12841872
[TBL] [Abstract][Full Text] [Related]
22. Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer.
Kouiavskaia DV; Berard CA; Datena E; Hussain A; Dawson N; Klyushnenkova EN; Alexander RB
J Immunother; 2009; 32(6):655-66. PubMed ID: 19483644
[TBL] [Abstract][Full Text] [Related]
23. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity.
Tjoa B; Boynton A; Kenny G; Ragde H; Misrock SL; Murphy G
Prostate; 1996 Jan; 28(1):65-9. PubMed ID: 8545283
[TBL] [Abstract][Full Text] [Related]
24. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA).
Salgaller ML; Lodge PA; McLean JG; Tjoa BA; Loftus DJ; Ragde H; Kenny GM; Rogers M; Boynton AL; Murphy GP
Prostate; 1998 May; 35(2):144-51. PubMed ID: 9568678
[TBL] [Abstract][Full Text] [Related]
25. Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients.
Kiessling A; Schmitz M; Stevanovic S; Weigle B; Hölig K; Füssel M; Füssel S; Meye A; Wirth MP; Rieber EP
Int J Cancer; 2002 Dec; 102(4):390-7. PubMed ID: 12402309
[TBL] [Abstract][Full Text] [Related]
26. Follow-up evaluation of a phase II prostate cancer vaccine trial.
Tjoa BA; Simmons SJ; Elgamal A; Rogers M; Ragde H; Kenny GM; Troychak MJ; Boynton AL; Murphy GP
Prostate; 1999 Jul; 40(2):125-9. PubMed ID: 10386473
[TBL] [Abstract][Full Text] [Related]
27. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer.
Meidenbauer N; Harris DT; Spitler LE; Whiteside TL
Prostate; 2000 May; 43(2):88-100. PubMed ID: 10754524
[TBL] [Abstract][Full Text] [Related]
28. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
[TBL] [Abstract][Full Text] [Related]
29. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA.
Barrou B; Benoît G; Ouldkaci M; Cussenot O; Salcedo M; Agrawal S; Massicard S; Bercovici N; Ericson ML; Thiounn N
Cancer Immunol Immunother; 2004 May; 53(5):453-60. PubMed ID: 14760510
[TBL] [Abstract][Full Text] [Related]
30. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
31. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin.
Wobser M; Keikavoussi P; Kunzmann V; Weininger M; Andersen MH; Becker JC
Cancer Immunol Immunother; 2006 Oct; 55(10):1294-8. PubMed ID: 16315030
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
[TBL] [Abstract][Full Text] [Related]
33. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors.
Lennerz V; Gross S; Gallerani E; Sessa C; Mach N; Boehm S; Hess D; von Boehmer L; Knuth A; Ochsenbein AF; Gnad-Vogt U; Zieschang J; Forssmann U; Woelfel T; Kaempgen E
Cancer Immunol Immunother; 2014 Apr; 63(4):381-94. PubMed ID: 24487961
[TBL] [Abstract][Full Text] [Related]
34. Survivin and PSMA Loaded Dendritic Cell Vaccine for the Treatment of Prostate Cancer.
Xi HB; Wang GX; Fu B; Liu WP; Li Y
Biol Pharm Bull; 2015; 38(6):827-35. PubMed ID: 25787895
[TBL] [Abstract][Full Text] [Related]
35. Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles.
Matsueda S; Takedatsu H; Yao A; Tanaka M; Noguchi M; Itoh K; Harada M
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6933-43. PubMed ID: 16203785
[TBL] [Abstract][Full Text] [Related]
36. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
Small EJ; Fratesi P; Reese DM; Strang G; Laus R; Peshwa MV; Valone FH
J Clin Oncol; 2000 Dec; 18(23):3894-903. PubMed ID: 11099318
[TBL] [Abstract][Full Text] [Related]
38. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide.
Perambakam S; Hallmeyer S; Reddy S; Mahmud N; Bressler L; DeChristopher P; Mahmud D; Nunez R; Sosman JA; Peace DJ
Cancer Immunol Immunother; 2006 Sep; 55(9):1033-42. PubMed ID: 16283303
[TBL] [Abstract][Full Text] [Related]
39. Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients.
Harada M; Matsueda S; Yao A; Ogata R; Noguchi M; Itoh K
Oncol Rep; 2004 Sep; 12(3):601-7. PubMed ID: 15289844
[TBL] [Abstract][Full Text] [Related]
40. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen.
Murphy G; Tjoa B; Ragde H; Kenny G; Boynton A
Prostate; 1996 Dec; 29(6):371-80. PubMed ID: 8977634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
